BiotechnologyTransformation NetworkRecently, Horimed Technology Co., Ltd. (hereinafter referred to as“Horimed”) announced the completion of nearly 100 million yuan in financing. This round of financing was jointly invested by Guanghua Wutong, Chengdu Science and Technology Investment, and Zhongtian Weiyi. Xingqiao Capital served as the exclusive financial advisor. This is Horimed's2025Another significant financing completed within the year will further accelerate the company's R&D, production, and commercialization of intravascular imaging and treatment-related products.Previously, HorimedCompleted over 100 million yuan in February 2025D++ Round Financing，ByNew Industry Investment, Huatai Zijin, Beiyang海棠 Fund, Jiuan Medical (002432.SZ), YuanSheng VenturesCo-investment.Value Core: Building an Integrated Platform for Vascular Interventional Diagnosis and Treatment that is Scarce in China
Horimed was founded in 2016.Focused on the independent research, production, and sales of Intravascular Ultrasound (IVUS) devices and catheters, Optical Coherence Tomography (OCT) devices and catheters, dual-catheter systems integrating IVUS/OCT in one unit, Fractional Flow Reserve (FFR) platforms based on IVUS and OCT for non-invasive blood flow reserve, single-source dual-modality OCT-NIRS technology combining OCT with Near-Infrared Spectroscopy (NIRS), and intravascular laser plaque ablation technology. Horimed masters optical, ultrasound, and catheter platform technologies and continuously innovates globally based on core technologies, aiming to provide an integrated pan-vascular solution based on imaging products for medical professionals and patients.
Dr. Shi-Yong Zhao, Co-founder and General Manager of HorimedZhaoshi Yong, Master's degree from Tianjin University and Ph.D. from Beijing Institute of Technology, has successively worked under the guidance of Academician Yao Jianquan and Academician Gu Ying in the research of all-solid-state lasers and biomedical photonics; served as the R&D Department Manager and Project Leader of Lepu Medical, a publicly listed company, with particular expertise in the development of active interventional products. Possesses extensive experience in medical product R&D, commercial operations, and enterprise management, skilled at building R&D teams, organizing domestic and international resources, rapidly iterating new products, and bringing them to market.Liu Zhiyong, Co-founder and Chairman of Horimed, holds a Bachelor's degree in Philosophy from Heilongjiang University and a Master's degree in Law. He has worked as a university teacher, government official, and lawyer, with extensive experience in investment and financing, as well as entrepreneurial endeavors.
The appeal of Horimed lies in its years of practical experience in the vascular intervention field, and more importantly, in its dedication to building a complete technical system and its irreplicable R&D capabilities. Horimed has been deeply engaged in intravascular ultrasound (IVUS) and Optical Coherence Tomography (OCT) With years of experience in the technical field, ranging from core components to complete equipment, from single products to systematic solutions.The full-chain layout.Horimed is one of the few companies in China that simultaneously mastersIVUSAndOCTEnterprise with Two Core Technologies, this kind of“Dual-Technology Approach”The ability to perform tasks in parallel has established its unique position in the field of precision diagnosis and treatment for vascular interventions.Simultaneous FusionOCTCompared with near-infrared spectroscopy (Near-Infrared Spectroscopy, NIRS) Single-source dual-modalOCT-NIRSThe success of the technology has further enabled Horimed to successfully establishOCT/IVUS/NIRSThree-modal imaging mode provides a more comprehensive solution for clinical diagnosis and treatment.Market Opportunities: AI Empowers Smart Healthcare, the Era of Precision Medicine Has Arrived
With the deepening of the concept of precision medicine and the increasing demand for surgical standardization, the need for real-time, precise imaging navigation during vascular interventional procedures is growing rapidly. Artificial intelligence technology has demonstrated significant advantages in medical image analysis, surgical path planning, and real-time navigation. China has a large population of cardiovascular disease patients, and the number of coronary intervention surgeries performed annually continues to rise. However, the penetration rate of intravascular imaging technology remains significantly lower compared to developed countries, representing a vast market potential and growth opportunity. Meanwhile, with the rising recommendation level for intraluminal imaging technology in clinical guidelines and the gradual improvement of medical insurance reimbursement policies, China's intravascular imaging market is about to enter a period of rapid growth.Horimed boasts a comprehensive product portfolio andAIThe technical accumulation in the field of smart healthcare has built up a comprehensive solution integrating image acquisition, intelligent analysis, and surgical guidance, ready to welcomeAIThe precision medicine market is fully prepared for an explosion.
Strategic Upgrade: Expanding from Cardiovascular to Pan-Vascular Ecosystem
Horimed is experiencing a transition from“Cardiovascular Specialist”To“Pan-Vascular Platform”TheStrategic Upgrade. Behind this transformation lies Horimed's profound insight into and forward-looking layout of the vascular disease diagnosis and treatment market. Based on in-depth market analysis and technical evaluation, as well as its technological reserves in the cardiovascular field, Horimed has expanded its layout to include cerebrovascular.OCT, Carotid ArteryOCT, Peripheral VesselsIVUS、4D ICE, laser ablation and other product pipelines. It is worth mentioning that,4D ICEThe product is compared in terms of operational difficulty, imaging field of view, modeling quality, etc.2D ICEThe product has more advantages.
This ecological expansion is due to Horimed's solid underlying technical foundation and the team's continuous self-iteration ability. The cross-field expansion of indications not only reduces the risk of technology development but also opens up broad development space for Horimed to further expand its business layout.
Source: Star Bridge Capital, Beiyang海棠, Genesis Ventures
